Market Cap 8.34B
Revenue (ttm) 4.13B
Net Income (ttm) 474.62M
EPS (ttm) N/A
PE Ratio 15.72
Forward PE 17.33
Profit Margin 11.49%
Debt to Equity Ratio 0.61
Volume 1,216,500
Avg Vol 896,344
Day's Range N/A - N/A
Shares Out 51.14M
Stochastic %K 71%
Beta 1.37
Analysts Sell
Price Target $180.60

Latest News on CRL

Charles River Introduces Global Biotech Incubator Program

Dec 5, 2024, 8:00 AM EST - 2 months ago

Charles River Introduces Global Biotech Incubator Program


Charles River Laboratories Announces Third-Quarter 2024 Results

Nov 6, 2024, 7:00 AM EST - 3 months ago

Charles River Laboratories Announces Third-Quarter 2024 Results


Charles River to Perform Plasmid Manufacturing for AAVantgarde

Jul 8, 2024, 8:00 AM EDT - 8 months ago

Charles River to Perform Plasmid Manufacturing for AAVantgarde


A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL

Jun 14, 2024, 1:27 PM EDT - 9 months ago

A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL

LLY AMGN TMO


Charles River Laboratories: Fair Valuation Against Fundamentals

May 31, 2024, 4:44 AM EDT - 9 months ago

Charles River Laboratories: Fair Valuation Against Fundamentals